Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Genitourinary tumours, non-prostate

4825 - Final results of a phase I study of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus Ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies


09 Sep 2017


Genitourinary tumours, non-prostate


Rosa Nadal


Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371


R. Nadal1, A. Mortazavi2, M. Stein3, S.K. Pal4, N. Davarpanah1, H.L. Parnes1, Y.M. Ning1, L.M. Cordes1, J. Lin1, M. Bagheri5, L. Linderberg1, M. Berniger1, S.M. Steinberg6, T. Moore4, T. Lancaster2, M. Aviles3, R. Costello1, D.P. Bottaro1, W.L. Dahut1, A.B. Apolo1

Author affiliations

  • 1 Medical Oncology, Center for Cancer Research-National Cancer Institute, 20892 - Bethesda/US
  • 2 Internal Medicine, James Cancer Hospital, The Ohio State University, Columbus/US
  • 3 Division Of Medical Oncology, The Cancer Institute of New Jersey, New Brunswick/US
  • 4 Medical Oncology, City of Hope, 91010 - Duarte/US
  • 5 Radiology And Imaging Sciences, Center for Cancer Research-National Cancer Institute, 20892 - Bethesda/US
  • 6 Biostatistics And Data Management Section, Center for Cancer Research-National Cancer Institute, 20892 - Bethesda/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4825


We report the updated safety and efficacy of CaboNivo and CaboNivoIpi in pts with mUC and other GU tumors (NCT02496208).


Primary objective was to determine the dose limiting toxicity (DLT) and recommended phase 2 dose (RP2D). We tested 7 dose levels (DL); 4 in part 1 (CaboNivo); 3 in part 2 (CaboNivoIpi). Part 1 pts received cabo PO daily/Nivo IV q2wks: DL1 Cabo 40mg/Nivo 1mg/kg, DL2 Cabo 40mg/Nivo 3mg/kg, DL3 Cabo 60mg/Nivo1mg/kg, DL4 Cabo 60mg/Nivo 3mg/kg. Part 2 pts received Cabo PO daily/Nivo/Ipi IV q3wks x4 cycles → Nivo IV q2wks: DL5 Cabo 40mg/Nivo1&Ipi 1mg/kg, DL6 Cabo 40mg/Nivo 3&Ipi 1mg/kg, DL7 Cabo 60mg/Nivo3&Ipi 1mg/kg. Adverse events (AEs) were graded by CTCAE v4.0. Other objectives: overall response rate (ORR), duration of response (DOR), progression-free survival (PFS) and overall survival (OS).


From 07/15/2015-04/25/2017, median(m) potential follow-up: 13.4 months(mo). 42 pts enrolled: 24 pts in part 1 (mUC n = 7; urachal (Ur) n = 4; germ cell tumor n = 4; prostate cancer (PC) n = 4; bladder squamous cell carcinoma (bSCC) n = 2; penile n = 1; sarcomatoid renal cell carcinoma (sRCC) n = 1; and trophoblastic n = 1); 18 pts in part 2 (mUC n = 8; penile n = 3; CRPC n = 5; sertoli n = 1; sRCC n = 1). Median age: 56 years (range 31-77), 90.5% male. Grade 3–4 AEs occurred in 67% of pts, mostly in part 1: hypophosphatemia (21%), neutropenia (21%), fatigue (12%), elevated lipase (12%); diarrhea, hypertension (HTN), dehydration, thrombocytopenia, proteinuria, and leukopenia (8% each); in part 2: hypophosphatemia (22%) HTN (17%); fatigue, nausea, lymphopenia, and elevated lipase (11% each). G3 immune-related AEs: aseptic meningitis (n = 1, DL1) and colitis (n = 1, DL5). No G5 toxicities or DLTs. RP2D for part 1: Cabo40mg/Nivo3mg/kg; for part 2: Cabo40mg/Nivo3&Ipi1mg/Kg. ORR=35%, 3CR (2mUC, 1SCC) & 11PR (3mUC, 2SCC, 2sRCC, 2Penile, 1Ur, 1PC). mDOR (CR+PR+SD): 7.1 mo [95% CI: 5.1-not reached], mPFS: 5.5 mo [95%CI: 4.5-12.8] and mOS was not reached. OS at 6&12 mo was 83.3%&64.3%.


CaboNivo and CaboNivoIpi showed durable clinical activity in mUC and rare GU malignancies with manageable toxicity.

Clinical trial identification

Trial Protocol Number: NCT02496208, release date: 07/15/2015

Legal entity responsible for the study

National Cancer Institute, National Health Institutes.


Cancer Therapy Evaluation Program


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.